Polymeric drug delivery systems for intraoral site-specific chemoprevention of oral cancer
Corresponding Author
Kashappa Goud H. Desai
Biopharmaceutical Product Sciences, GlaxoSmithKline, King of Prussia, Pennsylvania, 19406
Correspondence to: K. G. H. Desai; e-mail: [email protected]Search for more papers by this authorCorresponding Author
Kashappa Goud H. Desai
Biopharmaceutical Product Sciences, GlaxoSmithKline, King of Prussia, Pennsylvania, 19406
Correspondence to: K. G. H. Desai; e-mail: [email protected]Search for more papers by this authorAbstract
Oral cancer is among the most prevalent cancers in the world. Moreover, it is one of the major health problems and causes of death in many regions of the world. The traditional treatment modalities include surgical removal, radiation therapy, systemic chemotherapy, or a combination of these methods. In recent decades, there has been significant interest in intraoral site-specific chemoprevention via local drug delivery using polymeric systems. Because of its easy accessibility and clear visibility, the oral mucosa is amenable for local drug delivery. A variety of polymeric systems—such as gels, tablets, films, patches, injectable systems (e.g., millicylindrical implants, microparticles, and in situ-forming depots), and nanosized carriers (e.g., polymeric nanoparticles, nanofibers, polymer–drug conjugates, polymeric micelles, nanoliposomes, nanoemulsions, and polymersomes)—have been developed and evaluated for the local delivery of natural and synthetic chemopreventive agents. The findings of in vitro, ex vivo, and in vivo studies and the positive outcome of clinical trials demonstrate that intraoral site-specific drug delivery is an attractive, highly effective and patient-friendly strategy for the management of oral cancer. Intraoral site-specific drug delivery provides unique therapeutic advantages when compared to systemic chemotherapy. Moreover, intraoral drug delivery systems are self-administrable and can be removed when needed, increasing patient compliance. This article covers important aspects and advances related to the design, development, and efficacy of polymeric systems for intraoral site-specific drug delivery. © 2017 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 106B: 1383–1413, 2018.
Supporting Information
Additional Supporting Information may be found in the online version of this article.
Filename | Description |
---|---|
jbmb33943-sup-0001-suppinfo.docx872.4 KB | Supporting Information |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
REFERENCES
- 1 Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61(2): 69–90.
- 2 Markopoulos AK. Current aspects on oral squamous cell carcinoma. Open Dent J 2012; 6: 126–130.
- 3 Ram H, Sarkar J, Kumar H, Konwar R, Bhatt MLB, Mohammad S. Oral cancer: Risk factors and molecular pathogenesis. J Maxillofac Oral Surg 2011; 10(2): 132–137.
- 4 Chin D, Boyle GM, Porceddu S, Theile DR, Parsons PG, Coman WB. Head and neck cancer: Past, present and future. Expert Rev Anticancer Ther 2006; 6(7): 1111–1118.
- 5 Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015; 65(1): 5–29.
- 6 Sanderson RJ, Ironside JAD. Squamous cell carcinomas of the head and neck. Br Med J 2002; 325(7368): 822–827.
- 7 Epstein JB, Gorsky M, Cabay RJ, Day T, Gonsalves W. Screening for and diagnosis of oral premalignant lesions and oropharyngeal squamous cell carcinoma: Role of primary care physicians. Can Fam Physician 2008; 54(6): 870–875.
- 8 Neville BW, Day TA. Oral cancer and precancerous lesions. CA Cancer J Clin 2002; 52(4): 195–215.
- 9
Silverman S,
Gorsky M,
Lozada F. Oral leukoplakia and malignant transformation. A follow-up study of 257 patients. Cancer 1984; 53(3): 563–568.
10.1002/1097-0142(19840201)53:3<563::AID-CNCR2820530332>3.0.CO;2-F PubMed Web of Science® Google Scholar
- 10 Sdubba JJ. Oral leukoplakia. Crit Rev Oral Biol Med 1995; 6(2): 147–160.
- 11 Lumerman H, Freedman P, Kerpel S. Oral epithelial dysplasia and the development of invasive squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1995; 79(3): 321–329.
- 12 Vermorken JB, Specenier P. Optimal treatment for recurrent/metastatic head and neck cancer. Ann Oncol 2010; 21(Suppl 7): vii252–vii261.
- 13 Deng H, Sambrook PJ, Logan RM. The treatment of oral cancer: An overview for dental professionals. Aust Dent J 2011; 56(3): 244–252.
- 14 Jesse RH. The treatment of oral cancer. CA Cancer J Clin 1972; 22(4): 209–215.
- 15
Ray-Chaudhuri A,
Shah K,
Porter RJ. Radiotherapy: Oral management of patients who have received radiotherapy to the head and neck region. Vital 2013; 10(2): 30–36.
10.1038/vital1650 Google Scholar
- 16 Tannock IF. Combined modality treatment with radiotherapy and chemotherapy. Radiother Oncol 1989; 16(2): 83–101.
- 17 Campana JP, Meyers AD. The surgical management of oral cancer. Otolaryngol Clin North Am 2006; 39(2): 331–348.
- 18 Baker SR, Swanson NA. Cancer of the oral cavity and Mohs surgery. Dermatol Clin 1989; 7(4): 815–824.
- 19 Rogers SN, Brown JS, Woolgar JA, Lowe D, Magennis P, Shaw RJ, Sutton D, Errington D, Vaughan D. Survival following primary surgery for oral cancer. Oral Oncol 2009; 45(3): 201–211.
- 20 Shah JP, Gil Z. Current concepts in management of oral cancer–Surgery. Oral Oncol 2009; 45(4–5): 394–401.
- 21 McLeod HL, Evans WE. Oral cancer chemotherapy: The promise and the pitfalls. Clin Cancer Res 1999; 5(10): 2669–2671.
- 22 Da Silva SD, Hier M, Mlynarek A, Kowalski LP, Alaoui-Jamali MA. Recurrent oral cancer: Current and emerging therapeutic approaches. Front Pharmacol 2012; 3: 149.
- 23 Glick JH, Zehngebot LM, Taylor Iv SG. Chemotherapy for squamous cell carcinoma of the head and neck: A progress report. Am J Otolaryngol 1980; 1(4): 306–323.
- 24 O'Neill VJ, Twelves CJ. Oral cancer treatment: Developments in chemotherapy and beyond. Br J Cancer 2002; 87(9): 933–937.
- 25 Specenier PM, Vermorken JB. Current concepts for the management of head and neck cancer: Chemotherapy. Oral Oncol 2009; 45(4–5): 409–415.
- 26 Seoane-Mato D, Aragones N, Ferreras E, Garcia-Perez J, Cervantes-Amat M, Fernandez-Navarro P, Pastor-Barriuso R, Lopez-Abente G. Trends in oral cavity, pharyngeal, oesophageal and gastric cancer mortality rates in Spain, 1952–2006: An age-period-cohort analysis. BMC Cancer 2014; 14: 254.
- 27 Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007; 57(1): 43–66.
- 28 Turner L, Mupparapu M, Akintoye SO. Review of the complications associated with treatment of oropharyngeal cancer: A guide for the dental practitioner. Quintessence Int 2013; 44(3): 267–279.
- 29 Ushiyama M, Ikeda R, Yamaguchi H, Miyawaki A, Nitta T, Yamaguchi T, Tazitsu Y, Nishizawa Y, Shimodouzono Y, Hijioka H, Furukawa T, Akiyama SI, Nakamura N, Takeda Y, Yamada K. Adverse events of superselective intra-arterial infusion chemotherapy in patients with oral cancer. J Appl Ther Res 2009; 7(2): 58–64.
- 30 Bodhade AS, Dive AM. Chemoprevention of premalignant and malignant lesions of oral cavity: Recent trends. Eur J Dent 2013; 7(2): 246–250.
- 31 Garewal H, Meyskens F, Friedman S, Alberts D, Ramsey L. Oral cancer prevention: The case for carotenoids and anti-oxidant nutrients. Prev Med 1993; 22(5): 701–711.
- 32 Holpuch AS, Desai KGH, Schwendeman SP, Mallery SR. Optimizing therapeutic efficacy of chemopreventive agents: A critical review of delivery strategies in oral cancer chemoprevention clinical trials. J Carcinogen 2011; 10: 23.
- 33 Papadimitrakopoulou VA, Lee JJ, William WN, Martin JW, Thomas M, Kim ES, Khuri FR, Shin DM, Feng L, Hong WK, Lippman SM. Randomized trial of 13-cis retinoic acid compared with retinyl palmitate with or without beta-carotene in oral premalignancy. J Clin Oncol 2009; 27(4): 599–604.
- 34 Tsao AS, Liu D, Martin J, Tang X-m, Lee JJ, El-Naggar AK, Wistuba I, Culotta KS, Mao L, Gillenwater A, Sagesaka YM, Hong WK, Papadimitrakopoulou V. Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions. Cancer Prev Res (Phila) 2009; 2(11): 931–941.
- 35 Papadimitrakopoulou VA, William WN, Dannenberg AJ, Lippman SM, Lee JJ, Ondrey FG, Peterson DE, Feng L, Atwell A, El-Naggar AK, Nathan CA, Helman JI, Du B, Yueh B, Boyle JO. Pilot randomized phase II study of celecoxib in oral premalignant lesions. Clin Cancer Res 2008; 14(7): 2095–2101.
- 36 Saba NF, Hurwitz SJ, Kono SA, Yang CS, Zhao Y, Chen Z, Sica G, Müller S, Moreno-Williams R, Lewis M, Grist W, Chen AY, Moore CE, Owonikoko TK, Ramalingam S, Beitler JJ, Nannapaneni S, Shin HJC, Grandis JR, Khuri FR, Chen ZG, Shin DM. Chemoprevention of head and neck cancer with celecoxib and erlotinib: Results of a Phase IB and pharmacokinetic study. Cancer Prev Res (Phila) 2014; 7(3): 283–291.
- 37 Chiesa F, Tradati N, Grigolato R, Boracchi P, Biganzoli E, Crose N, Cavadini E, Formelli F, Costa L, Giardini R, Zurrida S, Costa A, De Palo G, Veronesi U. Randomized trial of fenretinide (4-HPR) to prevent recurrences, new localizations and carcinomas in patients operated on for oral leukoplakia: Long-term results. Int J Cancer 2005; 115(4): 625–629.
- 38 William WN, Lee JJ, Lippman SM, Martin JW, Tran HT, Sabichi AL, Kim ES, Feng L, Papadimitrakopoulou VA. Phase II chemoprevention trial with high dose fenretinide for oral pre-malignant lesions. Cancer Prev Res (Phila) 2009; 2(1): 22–26.
- 39 Conley B, O'Shaughnessy J, Prindiville S, Lawrence J, Chow C, Jones E, Merino MJ, Kaiser-Kupfer MI, Caruso RC, Podgor M, Goldspiel B, Venzon D, Danforth D, Wu S, Noone M, Goldstein J, Cowan KH, Zujewski J. Pilot trial of the safety, tolerability, and retinoid levels of N-(4-hydroxyphenyl) retinamide in combination with tamoxifen in patients at high risk for developing invasive breast cancer. J Clin Oncol 2000; 18(2): 275–283.
- 40 Rhee JC, Khuri FR, Shin DM. Advances in chemoprevention of head and neck cancer. Oncologist 2004; 9(3): 302–311.
- 41 Sankar V, Hearnden V, Hull K, Juras DV, Greenberg MS, Kerr AR, Lockhart PB, Patton LL, Porter S, Thornhill M. Local drug delivery for oral mucosal diseases: Challenges and opportunities. Oral Dis 2011; 17: 73–84.
- 42 Costa IDSM, Abranches RP, Garcia MTJ, Pierre MBR. Chitosan-based mucoadhesive films containing 5-aminolevulinic acid for buccal cancer's treatment. J Photochem Photobiol A Chem 2014; 140: 266–275.
- 43 Lv Q, Shen C, Li X, Shen B, Yu C, Xu P, Xu H, Han J, Yuan H. Mucoadhesive buccal films containing phospholipid-bile salts-mixed micelles as an effective carrier for Cucurbitacin B delivery. Drug Deliv 2015; 22(3): 351–358.
- 44 Ramineni SK, Cunningham LL, Dziubla TD, Puleo DA. Competing properties of mucoadhesive films designed for localized delivery of imiquimod. Biomater Sci 2013; 1(7): 753–762.
- 45 Ramineni SK, Cunningham LL, Dziubla TD, Puleo DA. Development of imiquimod-loaded mucoadhesive films for oral dysplasia. J Pharm Sci 2013; 102(2): 593–603.
- 46 Desai KGH, Mallery SR, Holpuch AS, Schwendeman SP. Development and in vitro-in vivo evaluation of fenretinide-loaded oral mucoadhesive patches for site-specific chemoprevention of oral cancer. Pharm Res 2011; 28(10): 2599–2609.
- 47 Holpuch AS, Phelps MP, Desai KGH, Chen W, Koutras GM, Han BB, Warner BM, Pei P, Seghi GA, Tong M, Border MB, Fields HW, Stoner GD, Larsen PE, Liu Z, Schwendeman SP, Mallery SR. Evaluation of a mucoadhesive fenretinide patch for local intraoral delivery: A strategy to reintroduce fenretinide for oral cancer chemoprevention. Carcinogenesis 2012; 33(5): 1098–1105.
- 48 Wu X, Desai KGH, Mallery SR, Holpuch AS, Phelps MP, Schwendeman SP. Mucoadhesive fenretinide patches for site-specific chemoprevention of oral cancer: Enhancement of oral mucosal permeation of fenretinide by coincorporation of propylene glycol and menthol. Mol Pharm 2012; 9(4): 937–945.
- 49 Mallery SR, Shenderova A, Pei P, Begum S, Ciminieri JR, Wilson RF, Casto BC, Schuller DE, Morse MA. Effects of 10-hydroxycamptothecin, delivered from locally injectable poly(lactide-co-glycolide) microspheres, in a murine human oral squamous cell carcinoma regression model. Anticancer Res 2001; 21(3B): 1713–1722.
- 50 Mallery SR, Stoner GD, Larsen PE, Fields HW, Rodrigo KA, Schwartz SJ, Tian Q, Dai J, Mumper RJ. Formulation and in-vitro and in-vivo evaluation of a mucoadhesive gel containing freeze dried black raspberries: Implications for oral cancer chemoprevention. Pharm Res 2007; 24(4): 728–737.
- 51 Mallery SR, Tong M, Shumway BS, Curran AE, Larsen PE, Ness GM, Kennedy KS, Blakey GH, Kushner GM, Vickers AM, Han B, Pei P, Stoner GD. Topical application of a mucoadhesive freeze-dried black raspberry gel induces clinical and histologic regression and reduces loss of heterozygosity events in premalignant oral intraepithelial lesions: Results from a multicentered, placebo-controlled clinical trial. Clin Cancer Res 2014; 20(7): 1910–1924.
- 52 Mallery SR, Zwick JC, Pei P, Tong M, Larsen PE, Shumway BS, Lu B, Fields HW, Mumper RJ, Stoner GD. Topical application of a bioadhesive black raspberry gel modulates gene expression and reduces cyclooxygenase 2 protein in human premalignant oral lesions. Cancer Res 2008; 68(12): 4945–4957.
- 53 Gavin A, Pham JTH, Wang D, Brownlow B, Elbayoumi TA. Layered nanoemulsions as mucoadhesive buccal systems for controlled delivery of oral cancer therapeutics. Int J Nanomed 2015; 10: 1569–1584.
- 54 Holpuch AS, Hummel GJ, Tong M, Seghi GA, Pei P, Ma P, Mumper RJ, Mallery SR. Nanoparticles for local drug delivery to the oral mucosa: Proof of principle studies. Pharm Res 2010; 27(7): 1224–1236.
- 55 Mazzarino L, Loch-Neckel G, Dos Santos Bubniak L, Mazzucco S, Santos-Silva MC, Borsali R, Lemos-Senna E. Curcumin-loaded chitosan-coated nanoparticles as a new approach for the local treatment of oral cavity cancer. J Nanosci Nanotechnol 2015; 15(1): 781–791.
- 56 Mohan A, Narayanan S, Sethuraman S, Krishnan UM. Novel resveratrol and 5-fluorouracil coencapsulated in PEGylated nanoliposomes improve chemotherapeutic efficacy of combination against head and neck squamous cell carcinoma. Biomed Res Int 2014:Article ID 424239.
- 57
Nordgård CT,
Bjørkøy A,
Draget KI. Guluronate oligosaccharides as enhancers of nanoparticle drug delivery in the oral cavity. Bioact Carbohydr Dietary Fibre 2015; 5(1): 72–78.
10.1016/j.bcdf.2014.12.004 Google Scholar
- 58 Schoener CA, Hutson HN, Peppas NA. pH-Responsive hydrogels with dispersed hydrophobic nanoparticles for the oral delivery of chemotherapeutics. J Biomed Mater Res A 2013; 101A(8): 2229–2236.
- 59 Singh H, Sharma R, Joshi M, Garg T, Goyal AK, Rath G. Transmucosal delivery of docetaxel by mucoadhesive polymeric nanofibers. Artif Cells Nanomed Biotechnol 2015; 43(4): 263–269.
- 60 Sorrell I, Shipley RJ, Hearnden V, Colley HE, Thornhill MH, Murdoch C, Webb SD. Combined mathematical modelling and experimentation to predict polymersome uptake by oral cancer cells. Nanomedicine 2014; 10(2): 339–348.
- 61 Mallery SR, Budendorf DE, Larsen MP, Pei P, Tong M, Holpuch AS, Larsen PE, Stoner GD, Fields HW, Chan KK, Ling Y, Liu Z. Effects of human oral mucosal tissue, saliva, and oral microflora on intraoral metabolism and bioactivation of black raspberry anthocyanins. Cancer Prev Res (Phila) 2011; 4(8): 1209–1221.
- 62 Desai KGH, Mallery SR, Schwendeman SP. Effect of formulation parameters on 2-methoxyestradiol release from injectable cylindrical poly(DL-lactide-co-glycolide) implants. Eur J Pharm Biopharm 2008; 70(1): 187–198.
- 63 Desai KGH, Mallery SR, Schwendeman SP. Formulation and characterization of injectable poly(DL-lactide-co- glycolide) implants loaded with N-acetylcysteine, a MMP inhibitor. Pharm Res 2008; 25(3): 586–597.
- 64 Desai KGH, Olsen KF, Mallery SR, Stoner GD, Schwendeman SP. Formulation and in vitro-in vivo evaluation of black raspberry extract-loaded PLGA/PLA injectable millicylindrical implants for sustained delivery of chemopreventive anthocyanins. Pharm Res 2010; 27(4): 628–643.
- 65 Wu W, Chen H, Shan F, Zhou J, Sun X, Zhang L, Gong T. A novel doxorubicin-loaded in situ forming gel based high concentration of phospholipid for intratumoral drug delivery. Mol Pharm 2014; 11(10): 3378–3385.
- 66 Wang Z, Polavaram R, Gooey J, Davis LH, Shapshay SM. Laser assisted topical ‘biofilm’ chemoprevention of oral cancer. Cancer Lett 2004; 215(1): 29–34.
- 67 Batchelor H. Bioadhesive dosage forms for esophageal drug delivery. Pharm Res 2005; 22(2): 175–181.
- 68 Collins JM. Pharmacologic rationale for regional drug delivery. J Clin Oncol 1984; 2(5): 498–504.
- 69 Hearnden V, Sankar V, Hull K, Juras DV, Greenberg M, Kerr AR, Lockhart PB, Patton LL, Porter S, Thornhill MH. New developments and opportunities in oral mucosal drug delivery for local and systemic disease. Adv Drug Deliv Rev 2012; 64(1): 16–28.
- 70 Otto SE. Advanced concepts in chemotherapy drug delivery: Regional therapy. J Intraven Nurs 1995; 18(4): 170–176.
- 71 Paderni C, Compilato D, Giannola LI, Campisi G. Oral local drug delivery and new perspectives in oral drug formulation. Oral Surg Oral Med Oral Pathol Oral Radiol 2012; 114(3): e25–e34.
- 72 Scholz OA, Wolff A, Schumacher A, Giannola LI, Campisi G, Ciach T, Velten T. Drug delivery from the oral cavity: Focus on a novel mechatronic delivery device. Drug Discov Today 2008; 13(5–6): 247–253.
- 73 Wolinsky JB, Colson YL, Grinstaff MW. Local drug delivery strategies for cancer treatment: Gels, nanoparticles, polymeric films, rods, and wafers. J Control Release 2012; 159(1): 14–26.
- 74 Shumway BS, Kresty LA, Larsen PE, Zwick JC, Lu B, Fields HW, Mumper RJ, Stoner GD, Mallery SR. Effects of a topically applied bioadhesive berry gel on loss of heterozygosity indices in premalignant oral lesions. Clin Cancer Res 2008; 14(8): 2421–2430.
- 75 Ugalde CM, Liu Z, Ren C, Chan KK, Rodrigo KA, Ling Y, Larsen PE, Chacon GE, Stoner GD, Mumper RJ, Fields HW, Mallery SR. Distribution of anthocyanins delivered from a bioadhesive black raspberry gel following topical intraoral application in normal healthy volunteers. Pharm Res 2009; 26(4): 977–986.
- 76
Rathbone MJ,
Pather I,
Şenel S. Overview of oral mucosal delivery. In: MJ Rathbone, S Şenel, I Pather, editors. Oral Mucosal Drug Delivery and Therapy. New York: Springer-Verlag; 2015. pp 17–30.
10.1007/978-1-4899-7558-4_2 Google Scholar
- 77 Mulshine JL, Atkinson JC, Greer RO, Papadimitrakopoulou VA, Van Waes C, Rudy S, Martin JW, Steinberg SM, Liewehr DJ, Avis I, Linnoila RI, Hewitt S, Lippman SM, Frye R, Cavanaugh PF. Randomized, double-blind, placebo-controlled Phase IIB trial of the cyclooxygenase inhibitor ketorolac as an oral rinse in oropharyngeal leukoplakia. Clin Cancer Res 2004; 10(5): 1565–1573.
- 78
Epstein JB,
Gorsky M. Topical application of vitamin A to oral leukoplakia. Cancer 1999; 86(6): 921–927.
10.1002/(SICI)1097-0142(19990915)86:6<921::AID-CNCR5>3.0.CO;2-6 CAS PubMed Web of Science® Google Scholar
- 79 Wang Z, Polavaram R, Fuentes CF, Shapshay SM. Topical chemoprevention of oral cancer with tretinoin “biofilm”. Arch Otolaryngol Head Neck Surg 2003; 129(8): 869–873.
- 80 Bagan J, Sarrion G, Jimenez Y. Oral cancer: Clinical features. Oral Oncol 2010; 46(6): 414–417.
- 81 Lippman SM, Sudbø J, Hong WK. Oral cancer prevention and the evolution of molecular-targeted drug development. J Clin Oncol 2005; 23(2): 346–356.
- 82 Williams HK. Molecular pathogenesis of oral squamous carcinoma. Mol Pathol 2000; 53(4): 165–172.
- 83 Dionne KR, Warnakulasuriya S, Binti Zain R, Cheong SC. Potentially malignant disorders of the oral cavity: Current practice and future directions in the clinic and laboratory. Int J Cancer 2015; 136(3): 503–515.
- 84 Fan CY. Genetic alterations in head and neck cancer: Interactions among environmental carcinogens, cell cycle control, and host DNA repair. Curr Oncol Rep 2001; 3(1): 66–71.
- 85 Colley HE, Hearnden V, Jones AV, Weinreb PH, Violette SM, MacNeil S, Thornhill MH, Murdoch C. Development of tissue-engineered models of oral dysplasia and early invasive oral squamous cell carcinoma. Br J Cancer 2011; 105(10): 1582–1592.
- 86 Park W, Owens JM. Future directions in the treatment of oral cancer. Otolaryngol Clin North Am (Phl) 2006; 39(2): 381–396.
- 87 Puts MTE, Tu HA, Tourangeau A, Howell D, Fitch M, Springall E, Alibhai SMH. Factors influencing adherence to cancer treatment in older adults with cancer: A systematic review. Ann Oncol 2014; 25(3): 564–577.
- 88 Byers RM. Factors affecting choice of initial therapy in oral cancer. Semin Surg Oncol 1995; 11(3): 183–189.
- 89 Nagpal JK, Das BR. Oral cancer: Reviewing the present understanding of its molecular mechanism and exploring the future directions for its effective management. Oral Oncol 2003; 39(3): 213–221.
- 90 Sporn MB. Approaches to prevention of epithelial cancer during the preneoplastic period. Cancer Res 1976; 36(7 pt 2): 2699–2702.
- 91 Lodi G, Sardella A, Bez C, Demarosi F, Carrassi A. Systematic review of randomized trials for the treatment of oral leukoplakia. J Dent Educ 2002; 66(8): 896–902.
- 92 Shen Z, Shen T, Wientjes MG, O'Donnell MA, Au JLS. Intravesical treatments of bladder cancer: Review. Pharm Res 2008; 25(7): 1500–1510.
- 93 Sood S, Shiff SJ, Yang CS, Chen X. Selection of topically applied non-steroidal anti-inflammatory drugs for oral cancer chemoprevention. Oral Oncol 2005; 41(6): 562–567.
- 94 Nudelman Z, Findler M, Barasch D, Nemirovski A, Pikovsky A, Kirmayer D, Basheer M, Gutkind JS, Friedman M, Czerninski R. Levels of sirolimus in saliva and blood following oral topical sustained-release varnish delivery system application. Cancer Chemother Pharmacol 2015; 75(5): 969–974.
- 95 Nudelman Z, Friedman M, Barasch D, Nemirovski A, Findler M, Pikovsky A, Gutkind JS, Czerninski R. Levels of sirolimus in saliva and blood following mouthwash application. Oral Dis 2014; 20(8): 768–772.
- 96 Gupta RC, Bansal SS, Aqil F, Jeyabalan J, Cao P, Kausar H, Russell GK, Munagala R, Ravoori S, Vadhanam MV. Controlled-release systemic delivery: A new concept in cancer chemoprevention. Carcinogenesis 2012; 33(8): 1608–1615.
- 97
Svider PF,
Warner BM,
Schwartz SJ,
Garshott DM,
Weinstein JD,
Fribley AM. Mucosal therapy for potentially malignant diseases and OSCC. In: AM Fribley, editor. Targeting Oral Cancer. New York: Springer; 2016. pp 283–299.
10.1007/978-3-319-27647-2_12 Google Scholar
- 98
Johnston PT. Anatomy and physiology of the oral mucosa. In: JM Rathbone, S Senel, I Pather, editors. Oral Mucosal Drug Delivery and Therapy. Boston: Springer; 2015. pp 1–15.
10.1007/978-1-4899-7558-4_1 Google Scholar
- 99 Patel VF, Liu F, Brown MB. Advances in oral transmucosal drug delivery. J Control Release 2011; 153(2): 106–116.
- 100 Collins LM, Dawes C. The surface area of the adult human mouth and thickness of the salivary film covering the teeth and oral mucosa. J Dent Res 1987; 66(8): 1300–1302.
- 101 Li B, Robinson JR. Preclinical assessment of oral mucosal drug delivery systems. In: TK Ghosh, WR Pfister, editors. Drug Delivery to the Oral Cavity: Molecules to the Market. Boca Raton: Taylor and Francis Group; 2005. pp 41–66.
- 102 De Vries ME, Bodde HE, Verhoef JC, Junginger HE. Developments in buccal drug delivery. Crit Rev Ther Drug Carrier Syst 1991; 8(3): 271–303.
- 103 Lesch CA, Squier CA, Cruchley A, Williams DM, Speight P. The permeability of human oral mucosa and skin to water. J Dent Res 1989; 68(9): 1345–1349.
- 104 Squier CA, Hall BK. The permeability of skin and oral mucosa to water and horseradish peroxidase as related to the thickness of the permeability barrier. J Invest Dermatol 1985; 84(3): 176–179.
- 105 Squier CA. Structure and barrier function of the epithelium of gastrointestinal and oral mucosa. In: HE Junginger, editor. Drug Targeting and Delivery: Concepts in Dosage Form Design. England: Ellis Horwood Limited; 1992. pp 45–56.
- 106 Şenel S, Hincal AA. Drug permeation enhancement via buccal route: Possibilities and limitations. J Control Release 2001; 72(1–3): 133–144.
- 107 Bhat PG, Flanagan DR, Donovan MD. The limiting role of mucus in drug absorption: Drug permeation through mucus solution. Int J Pharm 1995; 126(1–2): 179–187.
- 108 Dhiman MK, Dhiman A, Sawant KK. Transbuccal delivery of 5-fluorouracil: Permeation enhancement and pharmacokinetic study. AAPS PharmSciTech 2009; 10(1): 258–265.
- 109 Rathbone MJ, Tucker IG. Mechanisms, barriers and pathways of oral mucosal drug permeation. Adv Drug Deliv Rev 1993; 12(1–2): 41–60.
- 110 Sohi H, Ahuja A, Ahmad FJ, Khar RK. Critical evaluation of permeation enhancers for oral mucosal drug delivery. Drug Dev Ind Pharm 2010; 36(3): 254–282.
- 111 Xiaoling L, Venugopal M, Bhaskara RJ. Modulation of oral transmucosal permeability. In: TK Ghosh, WR Pfister, editors. Drug Delivery to the Oral Cavity. Boca Raton: Taylor and Francis Group; 2005. pp 67–87.
- 112 Priya B, Rashmi T, Bozena M. Basic biopharmaceutics of buccal and sublingual absorption. In: E Touitou, BW Barry, editors. Enhancement in Drug Delivery. Boca Raton: Taylor and Francis Group; 2011. pp 175–202.
- 113 Rudin CM, Cohen EEW, Papadimitrakopoulou VA, Silverman S, Recant W, El-Naggar AK, Stenson K, Lippman SM, Hong WK, Vokes EE. An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia. J Clin Oncol 2003; 21(24): 4546–4552.
- 114 Wertz PW, Swartzendruber DC, Squier CA. Regional variation in the structure and permeability of oral mucosa and skin. Adv Drug Deliv Rev 1993; 12(1–2): 1–12.
- 115 Mahalingam R, Ravivarapu H, Redkar S, Li X, Jasti BR. Transbuccal delivery of 5-aza-2 -deoxycytidine: Effects of drug concentration, buffer solution, and bile salts on permeation. AAPS PharmSciTech 2007; 8(3): E55.
- 116 Cid YP, Pedrazzi V, De Sousa VP, Pierre MBR. In vitro characterization of chitosan gels for buccal delivery of celecoxib: Influence of a penetration enhancer. AAPS PharmSciTech 2012; 13(1): 101–111.
- 117
Giannola IL,
De Caro V,
Sutera MF. Physical methods for enhancing oral mucosal delivery: Sonophoresis, iontophoresis and electroporation. In: JM Rathbone, S Senel, I Pather, editors. Oral Mucosal Drug Delivery and Therapy. Boston: Springer; 2015. pp 89–124.
10.1007/978-1-4899-7558-4_5 Google Scholar
- 118 Giannola LI, Sutera FM, De Caro V. Physical methods to promote drug delivery on mucosal tissues of the oral cavity. Expert Opin Drug Deliv 2013; 10(10): 1449–1462.
- 119
Nicolazzo AJ,
Finnin CB. In vivo and in vitro models for assessing drug absorption across the buccal mucosa. In: C Ehrhardt, K-J Kim, editors. Drug Absorption Studies: In Situ, In Vitro and In Silico Models. Boston, MA: Springer; 2008. pp 89–111.
10.1007/978-0-387-74901-3_4 Google Scholar
- 120
Smart JD,
Keegan G. Buccal drug delivery systems. In: H Wen, K Park, editors. Oral Controlled Release Formulation Design and Drug Delivery. Hoboken: John Wiley and Sons, Inc.; 2010. pp 169–184.
10.1002/9780470640487.ch11 Google Scholar
- 121 Nicolazzo JA, Reed BL, Finnin BC. Buccal penetration enhancers–How do they really work? J Control Release 2005; 105(1–2): 1–15.
- 122 Desai KGH, Pramod Kumar TM. Preparation and evaluation of a novel buccal adhesive system. AAPS PharmSciTech 2004; 5(3): 1–9.
- 123 Rathbone MJ, Drummond BK, Tucker IG. The oral cavity as a site for systemic drug delivery. Adv Drug Deliv Rev 1994; 13(1–2): 1–22.
- 124 Anders R, Merkle HP. Evaluation of laminated muco-adhesive patches for buccal drug delivery. Int J Pharm 1989; 49(3): 231–240.
- 125 Uchino H, Matsumura Y, Negishi T, Koizumi F, Hayashi T, Honda T, Nishiyama N, Kataoka K, Naito S, Kakizoe T. Cisplatin-incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats. Br J Cancer 2005; 93(6): 678–87.
- 126 Gaeta G, Gombos F, Femiano F, Battista C, Minghetti P, Montanari L, Satriano R, Argenziano G. Acitretin and treatment of the oral leucoplakias. A model to have an active molecules release. J Eur Acad Dermatol Venereol 2000; 14(6): 473–478.
- 127 Li Y, Li L-J, Zhang S-T, Wang L-J, Zhang Z, Gao N, Zhang Y-Y, Chen Q-M. In vitro and clinical studies of gene therapy with recombinant human adenovirus-p53 injection for oral leukoplakia. Clin Cancer Res 2009; 15(21): 6724–6731.
- 128 Place V, Darley P, Baricevic K, Ramans A, Pruitt B, Guittard G. Human buccal assay for evaluation of the mucosal irritation potential of drugs. Clin Pharmacol Ther 1988; 43(3): 233–241.
- 129 Hammersley N, Ferguson MM, Rennie JS. Topical bleomycin in the treatment of oral leukoplakia: A pilot study. Br J Oral Maxillofac Surg 1985; 23(4): 251–258.
- 130
Wong F,
Epstein J,
Millner A. Treatment of oral leukoplakia with topical bleomycin: A pilot study. Cancer 1989; 64(2): 361–365.
10.1002/1097-0142(19890715)64:2<361::AID-CNCR2820640203>3.0.CO;2-8 CAS PubMed Web of Science® Google Scholar
- 131 Helin-Tanninen M, Autio K, Keski-Rahkonen P, Naaranlahti T, Järvinen K. Comparison of six different suspension vehicles in compounding of oral extemporaneous nifedipine suspension for paediatric patients. Eur J Hosp Pharm Sci Pract 2012; 19(5): 432–437.
- 132 Epstein JB, Wong FLW, Millner A, Le ND. Topical bleomycin treatment of oral leukoplakia: A randomized double-blind clinical trial. Head and Neck 1994; 16(6): 539–544.
- 133 Gratieri T, Kalia YN. Targeted local simultaneous iontophoresis of chemotherapeutics for topical therapy of head and neck cancers. Int J Pharm 2014; 460(1–2): 24–27.
- 134 Li J, Gong C, Feng X, Zhou X, Xu X, Xie L, Wang R, Zhang D, Wang H, Deng P, Zhou M, Ji N, Zhou Y, Wang Y, Wang Z, Liao G, Geng N, Chu L, Qian Z, Wang Z, Chen Q. Biodegradable thermosensitive hydrogel for SAHA and DDP delivery: Therapeutic effects on oral squamous cell carcinoma xenografts. PLoS One 2012; 7(4): e33860.
- 135 Choi SG, Lee SE, Kang BS, Ng CL, Davaa E, Park JS. Thermosensitive and mucoadhesive sol-gel composites of paclitaxel/dimethyl-β-cyclodextrin for buccal delivery. PLoS One 2014; 9(10): e109090.
- 136 Aksungur P, Sungur A, Ünal S, İskit AB, Squier CA, Şenel S. Chitosan delivery systems for the treatment of oral mucositis: In vitro and in vivo studies. J Control Release 2004; 98(2): 269–279.
- 137 Bhattarai N, Gunn J, Zhang M. Chitosan-based hydrogels for controlled, localized drug delivery. Adv Drug Deliv Rev 2010; 62(1): 83–99.
- 138 Jacques Y, Nguyen-Xuan T, Ionescu E, Ravelli GP, Buri P, Baehni P, Gurny R. In vivo evaluation of hydrophilic and hydrophobic mucoadhesive semi-solid formulations containing sucralfate and lidocaine for intraoral use. Eur J Pharm Biopharm 1997; 43(1): 59–63.
- 139 Yaprak Karavana S, Güneri P, Ertan G. Benzydamine hydrochloride buccal bioadhesive gels designed for oral ulcers: Preparation, rheological, textural, mucoadhesive and release properties. Pharm Dev Technol 2009; 14(6): 623–631.
- 140 Andrews GP, Donnelly L, Jones DS, Curran RM, Morrow RJ, Woolfson AD, Malcolm RK. Characterization of the rheological, mucoadhesive, and drug release properties of highly structured gel platforms for intravaginal drug delivery. Biomacromolecules 2009; 10(9): 2427–2435.
- 141 Baloglu E, Karavana SY, Senyigit ZA, Guneri T. Rheological and mechanical properties of poloxamer mixtures as a mucoadhesive gel base. Pharm Dev Technol 2011; 16(6): 627–636.
- 142 Şenel S, İkinci G, Kaş S, Yousefi-Rad A, Sargon MF, Hıncal AA. Chitosan films and hydrogels of chlorhexidine gluconate for oral mucosal delivery. Int J Pharm 2000; 193(2): 197–203.
- 143 Ikinci G, Senel S, Akincibay H, Kas S, Ercis S, Wilson CG, Hincal AA. Effect of chitosan on a periodontal pathogen Porphyromonas gingivalis. Int J Pharm 2002; 235(1–2): 121–127.
- 144 Alsarra IA, Betigeri SS, Zhang H, Evans BA, Neau SH. Molecular weight and degree of deacetylation effects on lipase-loaded chitosan bead characteristics. Biomaterials 2002; 23(17): 3637–3644.
- 145 Hansen K, Kim G, Desai KGH, Patel H, Olsen KF, Curtis-Fisk J, Tocce E, Jordan S, Schwendeman SP. Feasibility investigation of cellulose polymers for mucoadhesive nasal drug delivery applications. Mol Pharm 2015; 12(8): 2732–2741.
- 146 Genta I, Perugini P, Pavanetto F. Different molecular weight chitosan microspheres: Influence on drug loading and drug release. Drug Dev Ind Pharm 1998; 24(8): 779–784.
- 147 Risbud MV, Hardikar AA, Bhat SV, Bhonde RR. pH-Sensitive freeze-dried chitosan-polyvinyl pyrrolidone hydrogels as controlled release system for antibiotic delivery. J Control Release 2000; 68(1): 23–30.
- 148 Boddé HE, De Vries ME, Junginger HE. Mucoadhesive polymers for the buccal delivery of peptides, structure-adhesiveness relationships. J Control Release 1990; 13(2–3): 225–231.
- 149 Salamat-Miller N, Chittchang M, Johnston TP. The use of mucoadhesive polymers in buccal drug delivery. Adv Drug Deliv Rev 2005; 57(11): 1666–1691.
- 150 Ivarsson D, Wahlgren M. Comparison of in vitro methods of measuring mucoadhesion: Ellipsometry, tensile strength and rheological measurements. Colloids Surf B Biointerfaces 2012; 92: 353–359.
- 151 Sudhakar Y, Kuotsu K, Bandyopadhyay AK. Buccal bioadhesive drug delivery–A promising option for orally less efficient drugs. J Control Release 2006; 114(1): 15–40.
- 152 Sobeck U, Fischer A, Biesalski HK. Uptake of vitamin A in buccal mucosal cells after topical application of retinyl palmitate: A randomised, placebo-controlled and double-blind trial. Br J Nutr 2003; 90(1): 69–74.
- 153 Papadimitrakopoulou VA, Clayman GL, Shin DM, Myers JN, Gillenwater AM, Goepfert H, El-Naggar AK, Lewin JS, Lippman SM, Hong WK. Biochemoprevention for dysplastic lesions of the upper aerodigestive tract. Arch Otolaryngol Head Neck Surg 1999; 125(10): 1083–1089.
- 154
Kasamatsu A,
Uzawa K,
Usukura K,
Koike K,
Nakashima D,
Ishigami T,
Fushimi K,
Ogawara K,
Shiiba M,
Tanzawa H. Loss of heterozygosity in oral cancer. Oral Sci Int 2011; 8(2): 37–43.
10.1016/S1348-8643(11)00027-9 Google Scholar
- 155 Chan G, Boyle JO, Yang EK, Zhang F, Sacks PG, Shah JP, Edelstein D, Soslow RA, Koki AT, Woerner BM, Masferrer JL, Dannenberg AJ. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res 1999; 59(5): 991–994.
- 156 Packhaeuser CB, Schnieders J, Oster CG, Kissel T. In situ forming parenteral drug delivery systems: An overview. Eur J Pharm Biopharm 2004; 58(2): 445–455.
- 157 Hwang YS, Chiang PR, Hong WH, Chiao CC, Chu IM, Hsiue GH, Shen CR. Study in vivo intraocular biocompatibility of in situ gelation hydrogels: Poly(2-ethyl oxazoline)-block-poly(epsilon-caprolactone)-block-poly(2-ethyl oxazoline) copolymer, matrigel and pluronic F127. PLoS One 2013; 8(7): e67495.
- 158 Gutowska A, Jeong B, Jasionowski M. Injectable gels for tissue engineering. Anat Rec 2001; 263(4): 342–349.
- 159 Wang Z, Polavaram R, Shapshay SM. Topical inhibition of oral carcinoma cell with polymer delivered celecoxib. Cancer Lett 2003; 198(1): 53–58.
- 160 Gorsky M, Epstein JB. The effect of retinoids on premalignant oral lesions: Focus on topical therapy. Cancer 2002; 95(6): 1258–1264.
- 161 Campisi G, Giannola LI, Fucarino A, Gammazza AM, Pitruzzella A, Marcianò V, de Caro V, Siragusa MG, Giandalia G, Compilato D, Holgate ST, Davies DE, Farina F, Zummo G, Paderni C, Bucchieri F. Medium-term culture of primary oral squamous cell carcinoma in a three-dimensional model: Effects on cell survival following topical 5-fluororacile delivery by drug-loaded matrix tablets. Curr Pharm Des 2012; 18(34): 5411–5420.
- 162 Giannola LI, De Caro V, Giandalia G, Siragusa MG, Paderni C, Campisi G, Florena AM. 5-Fluorouracil buccal tablets for locoregional chemotherapy of oral squamous cell carcinoma: Formulation, drug release and histological effects on reconstituted human oral epithelium and porcine buccal mucosa. Curr Drug Deliv 2010; 7(2): 109–117.
- 163 Ramineni SK, Dziubla TD, Cunningham Jr LL, Puleo DA. Local delivery of imiquimod in hamsters using mucoadhesive films and their residence time in human patients. Oral Surg Oral Med Oral Pathol Oral Radiol 2014; 118(6): 665–673.
- 164 Morales JO, McConville JT. Manufacture and characterization of mucoadhesive buccal films. Eur J Pharm Biopharm 2011; 77(2): 187–99.
- 165 Bayrak Z, Tas C, Tasdemir U, Erol H, Ozkan CK, Savaser A, Ozkan Y. Formulation of zolmitriptan sublingual tablets prepared by direct compression with different polymers: In vitro and in vivo evaluation. Eur J Pharm Biopharm 2011; 78(3): 499–505.
- 166 Andreadis C, Vahtsevanos K, Sidiras T, Thomaidis I, Antoniadis K, Mouratidou D. 5-Fluorouracil and cisplatin in the treatment of advanced oral cancer. Oral Oncol 2003; 39(4): 380–385.
- 167 Baker SD, Khor SP, Adjei AA, Doucette M, Spector T, Donehower RC, Grochow LB, Sartorius SE, Noe DA, Hohneker JA, Rowinsky EK. Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase. J Clin Oncol 1996; 14(12): 3085–3096.
- 168 Oldfield V, Keating GM, Perry CM. Imiquimod: In superficial basal cell carcinoma. Am J Clin Dermatol 2005; 6(3): 195–200.
- 169 Gkoulioni V, Eleftheriadou A, Yiotakis I, Ferekidou E, Chrisovergis A, Lazaris A, Kandiloros D. The efficacy of imiquimod on dysplastic lesions of the oral mucosa: An experimental model. Anticancer Res 2010; 30(7): 2891–2896.
- 170 Kokate A, Li X, Jasti B. Transport of a novel anti-cancer agent, fenretinide across Caco-2 monolayers. Invest New Drugs 2007; 25(3): 197–203.
- 171 Okuda T, Kawakami S, Higuchi Y, Satoh T, Oka Y, Yokoyama M, Yamashita F, Hashida M. Enhanced in vivo antitumor efficacy of fenretinide encapsulated in polymeric micelles. Int J Pharm 2009; 373(1–2): 100–106.
- 172 William Jr WN, Papadimitrakopoulou V, Lee JJ, Mao L, Cohen EWH, Lin H, Gillenwater AM, Martin JW, Lingen MW, Boyle JO, Shin DM, Vigneswaran N, Shinn N, Heymach JV, Wistuba II, Tang X, Kim ES, Saintigny P, Blair EA, Meiller T, Gutkind JS, Myers J, El-Naggar A, Lippman SM. Erlotinib and the risk of oral cancer: The erlotinib prevention of oral cancer (epoc) randomized clinical trial. JAMA Oncol 2016; 2(2): 209–216.
- 173 Ramshankar V, Krishnamurthy A. Chemoprevention of oral cancer: Green tea experience. J Nat Sci Biol Med 2014; 5(1): 3–7.
- 174 Freemantle SJ, Spinella MJ, Dmitrovsky E. Retinoids in cancer therapy and chemoprevention: Promise meets resistance. Oncogene 2003; 22(47): 7305–7315.
- 175 Wischke C, Zhang Y, Mittal S, Schwendeman SP. Development of PLGA-based injectable delivery systems for hydrophobic fenretinide. Pharm Res 2010; 27(10): 2063–2074.
- 176 Shenderova A, Burke TG, Schwendeman SP. Stabilization of 10-hydroxycamptothecin in poly(lactide-co-glycolide) microsphere delivery vehicles. Pharm Res 1997; 14(10): 1406–1414.
- 177 Shenderova A, Burke TG, Schwendeman SP. The acidic microclimate in poly(lactide-co-glycolide) microspheres stabilizes camptothecins. Pharm Res 1999; 16(2): 241–243.
- 178 Jeong YI, Song JG, Kang SS, Ryu HH, Lee YH, Choi C, Shin BA, Kim KK, Ahn KY, Jung S. Preparation of poly(DL-lactide-co-glycolide) microspheres encapsulating all-trans retinoic acid. Int J Pharm 2003; 259(1–2): 79–91.
- 179 Choi Y, Kim SY, Kim SH, Yang J, Park K, Byun Y. Inhibition of tumor growth by biodegradable microspheres containing all-trans-retinoic acid in a human head-and-neck cancer xenograft. Int J Cancer 2003; 107(1): 145–148.
- 180 Choi Y, Kim SY, Kim SH, Park TG, Moon HT, Byun Y. In vivo biocompatibility studies of poly(D,L-lactide)/poly(ethylene glycol)-poly(L-lactide) microspheres containing all-trans-retinoic acid. J Biomater Sci Polym Ed 2002; 13(3): 301–322.
- 181 Choi Y, Kim SY, Kim SH, Lee KS, Kim C, Byun Y. Long-term delivery of all-trans-retinoic acid using biodegradable PLLA/PEG-PLLA blended microspheres. Int J Pharm 2001; 215(1–2): 67–81.
- 182 Hernán Pérez de la Ossa D, Lorente M, Gil-Alegre ME, Torres S, García-Taboada E, Aberturas MdR, Molpeceres J, Velasco G, Torres-Suárez AI. Local delivery of cannabinoid-loaded microparticles inhibits tumor growth in a murine xenograft model of glioblastoma multiforme. PLoS One 2013; 8(1): e54795.
- 183 Desai KGH, Kadous S, Schwendeman SP. Gamma irradiation of active self-healing PLGA microspheres for efficient aqueous encapsulation of vaccine antigens. Pharm Res 2013; 30(7): 1768–1778.
- 184 Desai KGH, Schwendeman SP. Active self-healing encapsulation of vaccine antigens in PLGA microspheres. J Control Release 2013; 165(1): 62–74.
- 185 Reinhold SE, Desai KGH, Zhang L, Olsen KF, Schwendeman SP. Self-healing microencapsulation of biomacromolecules without organic solvents. Angew Chem Int Ed 2012; 51(43): 10800–10803.
- 186 Sophocleous AM, Desai KGH, Mazzara JM, Tong L, Cheng JX, Olsen KF, Schwendeman SP. The nature of peptide interactions with acid end-group PLGAs and facile aqueous-based microencapsulation of therapeutic peptides. J Control Release 2013; 172(3): 662–670.
- 187 Heller J. Biodegradable polymers in controlled drug delivery. Crit Rev Ther Drug Carrier Syst 1984; 1(1): 39–90.
- 188 Okada H, Toguchi H. Biodegradable microspheres in drug delivery. Crit Rev Ther Drug Carrier Syst 1995; 12(1): 1–99.
- 189 Bala I, Hariharan S, Ravi Kumar MNV. PLGA nanoparticles in drug delivery: The state of the art. Crit Rev Ther Drug Carrier Syst 2004; 21(5): 387–422.
- 190 Ben-Shabat S, Kumar N, Domb AJ. PEG-PLA block copolymer as potential drug carrier: Preparation and characterization. Macromol Biosci 2006; 6(12): 1019–1025.
- 191 Gad HA, El-Nabarawi MA, Abd El-Hady SS. Formulation and evaluation of PLA and PLGA in situ implants containing secnidazole and/or doxycycline for treatment of periodontitis. AAPS PharmSciTech 2008; 9(3): 878–884.
- 192 Astaneh R, Erfan M, Moghimi H, Mobedi H. Changes in morphology of in situ forming PLGA implant prepared by different polymer molecular weight and its effect on release behavior. J Pharm Sci 2009; 98(1): 135–145.
- 193 Sartor O. Eligard: Leuprolide acetate in a novel sustained-release delivery system. Urology 2003; 61(2 Suppl 1): 25–31.
- 194 Sulfikkarali N, Krishnakumar N, Manoharan S, Nirmal RM. Chemopreventive efficacy of naringenin-loaded nanoparticles in 7,12-dimethylbenz(a)anthracene induced experimental oral carcinogenesis. Pathol Oncol Res 2013; 19(2): 287–296.
- 195 Ma Y, Boese SE, Luo Z, Nitin N, Gill HS. Drug coated microneedles for minimally-invasive treatment of oral carcinomas: Development and in vitro evaluation. Biomed Microdevices 2015; 17(2):Article 44.
- 196 Derakhshandeh K, Hochhaus G, Dadashzadeh S. In-vitro cellular uptake and transport study of 9-nitrocamptothecin PLGA nanoparticles across caco-2 cell monolayer model. Iran J Pharm Res 2011; 10(3): 425–434.
- 197 Satapathy SR, Siddharth S, Das D, Nayak A, Kundu CN. Enhancement of cytotoxicity and inhibition of angiogenesis in oral cancer stem cells by a hybrid nanoparticle of bioactive quinacrine and silver: Implication of base excision repair cascade. Mol Pharm 2015; 12(11): 4011–4025.
- 198 Ünal H, Öztürk N, Bilensoy E. Formulation development, stability and anticancer efficacy of core-shell cyclodextrin nanocapsules for oral chemotherapy with camptothecin. Beilstein J Org Chem 2015; 11: 204–212.
- 199 Wang A, Li S. Hydroxycamptothecin-loaded nanoparticles enhance target drug delivery and anticancer effect. BMC Biotechnol 2008; 8: 46.
- 200 Li S, Wang A, Jiang W, Guan Z. Pharmacokinetic characteristics and anticancer effects of 5-fluorouracil loaded nanoparticles. BMC Cancer 2008; 8: 103.
- 201 Yu D, Wang A, Huang H, Chen Y. PEG-PBLG nanoparticle-mediated HSV-TK/GCV gene therapy for oral squamous cell carcinoma. Nanomedicine (Lond) 2008; 3(6): 813–821.
- 202 Zhao H, Feng H, Liu D, Liu J, Ji N, Chen F, Luo X, Zhou Y, Dan H, Zeng X, Li J, Sun C, Meng J, Ju X, Zhou M, Yang H, Li L, Liang X, Chu L, Jiang L, He Y, Chen Q. Self-assembling monomeric nucleoside molecular nanoparticles loaded with 5-FU enhancing therapeutic efficacy against oral cancer. ACS Nano 2015; 9(10): 9638–9651.
- 203 Arulmozhi V, Pandian K, Mirunalini S. Ellagic acid encapsulated chitosan nanoparticles for drug delivery system in human oral cancer cell line (KB). Colloids Surf B Biointerfaces 2013; 110: 313–320.
- 204 Jeong YI, Kim ST, Jin SG, Ryu HH, Jin YH, Jung TY, Kim IY, Jung S. Cisplatin-incorporated hyaluronic acid nanoparticles based on ion-complex formation. J Pharm Sci 2008; 97(3): 1268–1276.
- 205 Cai S, Alhowyan AAB, Yang Q, Forrest WCM, Shnayder Y, Forrest ML. Cellular uptake and internalization of hyaluronan-based doxorubicin and cisplatin conjugates. J Drug Target 2014; 22(7): 648–657.
- 206 Cai S, Xie Y, Davies NM, Cohen MS, Forrest ML. Pharmacokinetics and disposition of a localized lymphatic polymeric hyaluronan conjugate of cisplatin in rodents. J Pharm Sci 2010; 99(6): 2664–2671.
- 207 Cai S, Xie Y, Davies NM, Cohen MS, Forrest ML. Carrier-based intralymphatic cisplatin chemotherapy for the treatment of metastatic squamous cell carcinoma of the head and neck. Ther Deliv 2010; 1(2): 237–245.
- 208 Li P, Zhou G, Zhu X, Li G, Yan P, Shen L, Xu Q, Hamblin MR. Photodynamic therapy with hyperbranched poly(ether-ester) chlorin(e6) nanoparticles on human tongue carcinoma CAL-27 cells. Photodiagnosis Photodyn Ther 2012; 9(1): 76–82.
- 209 Nie S, Hsiao WLW, Pan W, Yang Z. Thermoreversible Pluronic® F127-based hydrogel containing liposomes for the controlled delivery of paclitaxel: In vitro drug release, cell cytotoxicity, and uptake studies. Int J Nanomed 2011; 6: 151–166.
- 210 Endo K, Ueno T, Kondo S, Wakisaka N, Murono S, Ito M, Kataoka K, Kato Y, Yoshizaki T. Tumor-targeted chemotherapy with the nanopolymer-based drug NC-6004 for oral squamous cell carcinoma. Cancer Sci 2013; 104(3): 369–374.
- 211 Alibolandi M, Ramezani M, Abnous K, Sadeghi F, Hadizadeh F. Comparative evaluation of polymersome versus micelle structures as vehicles for the controlled release of drugs. J Nanopart Res 2015; 17(2): 1–16.
- 212 Ding XQ, Chen D, Wang AX, Li S, Chen Y, Wang J. Antitumor effects of hydroxycamptothecin-loaded poly[ethylene glycol]-poly [gamma-benzyl-L-glutamate] micelles against oral squamous cell carcinoma. Oncol Res 2007; 16(7): 313–323.
- 213 Murdoch C, Reeves KJ, Hearnden V, Colley H, Massignani M, Canton I, Madsen J, Blanazs A, Armes SP, Lewis AL, MacNeil S, Brown NJ, Thornhill MH, Battaglia G. Internalization and biodistribution of polymersomes into oral squamous cell carcinoma cells in vitro and in vivo. Nanomedicine 2010; 5(7): 1025–1036.
- 214 Colley HE, Hearnden V, Avila-Olias M, Cecchin D, Canton I, Madsen J, Macneil S, Warren N, Hu K, McKeating JA, Armes SP, Murdoch C, Thornhill MH, Battaglia G. Polymersome-mediated delivery of combination anticancer therapy to head and neck cancer cells: 2D and 3D in vitro evaluation. Mol Pharm 2014; 11(4): 1176–1188.
- 215 Liu L, Tang Y, Gao C, Li Y, Chen S, Xiong T, Li J, Du M, Gong Z, Chen H, Liu L, Yao P. Characterization and biodistribution in vivo of quercetin-loaded cationic nanostructured lipid carriers. Colloids Surf B Biointerfaces 2014; 115: 125–131.
- 216 Govender T, Stolnik S, Garnett MC, Illum L, Davis SS. PLGA nanoparticles prepared by nanoprecipitation: Drug loading and release studies of a water soluble drug. J Control Release 1999; 57(2): 171–185.
- 217 Schubert S, Delaney JJT, Schubert US. Nanoprecipitation and nanoformulation of polymers: From history to powerful possibilities beyond poly(lactic acid). Soft Matter 2011; 7(5): 1581–1588.
- 218 Vauthier C, Bouchemal K. Methods for the preparation and manufacture of polymeric nanoparticles. Pharm Res 2009; 26(5): 1025–1058.
- 219 Desai KGH. Chitosan nanoparticles prepared by ionotropic gelation: An overview of recent advances. Crit Rev Ther Drug Carrier Syst 2016; 33(2): 107–158.
- 220 Gallant JN, Allen JE, Smith CD, Dicker DT, Wang W, Dolloff NG, Navaraj A, El-Deiry WS. Quinacrine synergizes with 5-fluorouracil and other therapies in colorectal cancer. Cancer Biol Ther 2011; 12(3): 239–251.
- 221 Hu X, Liu S, Zhou G, Huang Y, Xie Z, Jing X. Electrospinning of polymeric nanofibers for drug delivery applications. J Control Release 2014; 185: 12–21.
- 222 Sharma R, Singh H, Joshi M, Sharma A, Garg T, Goyal AK, Rath G. Recent advances in polymeric electrospun nanofibers for drug delivery. Crit Rev Ther Drug Carrier Syst 2014; 31(3): 187–217.
- 223 Ringsdorf H. Structure and properties of pharmacologically active polymers. J Polym Sci Polym Symp 1975; 51(1): 135–153.
- 224 Khandare J, Minko T. Polymer-drug conjugates: Progress in polymeric prodrugs. Prog Polym Sci 2006; 31(4): 359–397.
- 225 Li C, Wallace S. Polymer-drug conjugates: Recent development in clinical oncology. Adv Drug Deliv Rev 2008; 60(8): 886–898.
- 226 Vicent MJ, Duncan R. Polymer conjugates: Nanosized medicines for treating cancer. Trends Biotechnol 2006; 24(1): 39–47.
- 227 Wadhwa S, Mumper RJ. Polymer-drug conjugates for anticancer drug delivery. Crit Rev Ther Drug Carrier Syst 2015; 32(3): 215–245.
- 228 Duncan R. Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer 2006; 6(9): 688–701.
- 229 Croy SR, Kwon GS. Polymeric micelles for drug delivery. Curr Pharm Des 2006; 12(36): 4669–4684.
- 230 Cho HK, Cheong IW, Lee JM, Kim JH. Polymeric nanoparticles, micelles and polymersomes from amphiphilic block copolymer. Korean J Chem Eng 2010; 27(3): 731–740.
- 231 Zhang X, Huang Y, Li S. Nanomicellar carriers for targeted delivery of anticancer agents. Ther Deliv 2014; 5(1): 53–68.
- 232 Mozafari MR. Nanoliposomes: Preparation and analysis. Methods Mol Biol 2010; 605: 29–50.
- 233 Khosravi-Darani K, Mozafari MR. Nanoliposome potentials in nanotherapy: A concise overview. Int J Nanosci Nanotechnol 2010; 6(1): 3–13.
- 234 Abreu AS, Castanheira EM, Queiroz M-JR, Ferreira PM, Vale-Silva LA, Pinto E. Nanoliposomes for encapsulation and delivery of the potential antitumoral methyl 6-methoxy-3-(4-methoxyphenyl)-1H-indole-2-carboxylate. Nanoscale Res Lett 2011; 6(1): 1–6.
- 235 Jaiswal M, Dudhe R, Sharma PK. Nanoemulsion: An advanced mode of drug delivery system. 3 Biotech 2015; 5(2): 123–127.
- 236 Gupta A, Eral HB, Hatton TA, Doyle PS. Nanoemulsions: Formation, properties and applications. Soft Matter 2016; 12(11): 2826–2841.
- 237 Lee JS, Zhou W, Meng F, Zhang D, Otto C, Feijen J. Thermosensitive hydrogel-containing polymersomes for controlled drug delivery. J Control Release 2010; 146(3): 400–408.
- 238 Sanson C, Schatz C, Le Meins J-F, Soum A, Thévenot J, Garanger E, Lecommandoux S. A simple method to achieve high doxorubicin loading in biodegradable polymersomes. J Control Release 2010; 147(3): 428–435.
- 239 Hearnden V, Lomas H, Macneil S, Thornhill M, Murdoch C, Lewis A, Madsen J, Blanazs A, Armes S, Battaglia G. Diffusion studies of nanometer polymersomes across tissue engineered human oral mucosa. Pharm Res 2009; 26(7): 1718–1728.
- 240 Alcantar NA, Aydil ES, Israelachvili JN. Polyethylene glycol-coated biocompatible surfaces. J Biomed Mater Res 2000; 51(3): 343–351.
- 241 Minghetti P, Colombo A, Montanari L, Gaeta GM, Gombos F. Buccoadhesive slow-release tablets of acitretin: Design and ‘in vivo’ evaluation. Int J Pharm 1998; 169(2): 195–202.
- 242 Piattelli A, Fioroni M, Santinelli A, Rubini C. bcl-2 expression and apoptotic bodies in 13-cis-retinoic acid (isotretinoin)-topically treated oral leukoplakia: A pilot study. Oral Oncol 1999; 35(3): 314–320.
- 243 Damascelli B, Patelli GL, Lanocita R, Tolla GD, Frigerio LF, Marchianò A, Garbagnati F, Spreafico C, Tichà V, Gladin CR, Palazzi M, Crippa F, Oldini C, Calò S, Bonaccorsi A, Mattavelli F, Costa L, Mariani L, Cantù G. A novel intraarterial chemotherapy using paclitaxel in albumin nanoparticles to treat advanced squamous cell carcinoma of the tongue: Preliminary findings. AJR Am J Roentgenol 2003; 181(1): 253–260.
- 244 Tradati N, Chiesa F, Rossi N, Grigolato R, Formelli F, Costa A, De Palo G. Successful topical treatment of oral lichen planus and leukoplakias with fenretinide (4-HPR). Cancer Lett 1994; 76(2–3): 109–111.
- 245
Epstein JB,
Gorsky M,
Wong FLW,
Millner A. Topical bleomycin for the treatment of dysplastic oral leukoplakia. Cancer 1998; 83(4): 629–634.
10.1002/(SICI)1097-0142(19980815)83:4<629::AID-CNCR1>3.0.CO;2-F CAS PubMed Web of Science® Google Scholar